CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
High ImpactOriginal article

Viridian Therapeutics’ stock up 35% after Phase III TED data release

Phase 3positiveelegrobartPositive
AI Analysis

Summary

Viridian Therapeutics reported positive Phase III trial data for elegrobart in thyroid eye disease (TED) and is filing a BLA, resulting in a 35% stock increase.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Two positive Phase III trials

Importance:8/10
Sentiment:
0.80
Phase IIIBLA filingTEDelegrobartpositive data
Related Companies

Read the original article

Published by Clinical Trials Arena on May 6, 2026 11:13 AM

Read Original